Most of this is from Biopharma-Reporter.com, which looks promising as a future source of news in this space:
- France will ramp up its vaccine manufacturing efforts, with
- "CDMO Recipharm will start production for Moderna at its Monts facility next month; while Delpharm will manufacture the Pfizer/BioNTech vaccine in Saint-Rémy-sur-Avre from April. In May, Fareva is set to follow suit for CureVac’s vaccine."
- Other vaccines in the pipeline include "Johnson & Johnson, CureVac, Sanofi/GSK, Novavax and Valneva: with CureVac, J&J and Novavax being the most advanced of these."
- New Zealand has approved the AstraZeneca, Moderna, and Janssen vaccines.
- AstraZeneca says it could take 6-9 months to make vaccines for variant SARS-CoV-2 viruses.
- AstraZeneca has a deal with German IDT Biologika to increase production of its COVID-19 vaccine.
- German contract manufacturing firm Rentschler is expanding its UK presence, to increase materials necessary for vectored virus vaccine manufacture.
- The Biden administration has announced there should be 200 million vaccine doses by July, which should be enough to get everyone who wants a shot.
- CureVac's COVID-19 vaccine has started the approval process with the European Medicines Agency, the third mRNA vaccine in the pipeline.
- CureVac is also plotting how it will react to novel SARS-CoV-2 strains, expanding research in the UK.
No comments:
Post a Comment